Diagnostics Company Opens in Berlin

Astra Biotech GmbH, Berlin, Germany is a new company whose core focus is the development of innovative diagnostics for the identification of an individual’s predisposition to disease, offering a portfolio of assays in areas such as allergies, genetically associated disorders, hormonal dysfunctions, and others.

Key targets so far are for osteoporosis, a condition which affects over 75 million people worldwide and thrombosis, a major fatal disease in developed countries. Other diagnostic kits include one for the determination of an individual’s susceptibility or resistance to oral anticoagulants as well as niche diseases. A new array technology for improved hybridisation will also become available shortly said the company.

Alexandra Ghica-Cantacuzino, Head of International Sales & Marketing at Astra Biotech GmbH, said: “Our contribution is to optimise patient healthcare by early diagnosis of potential risks to individuals though innovative assays. In Astra Biotech we believe laboratories must understand patient needs and be more specific in their approach to the identification of risk factors so that early intervention helps to minimise any long term effects of a disease. Our target is to continue to assist clinicians, doctors, hospital staff and medical oriented laboratories to improve overall healthcare standards.“

As part of their expansion program Astra Biotech GmbH are now looking to strengthen their distribution channels in Europe and Asia plus are looking for possible OEM manufacturing opportunities for future products.